Avalo Therapeutics Purchases Optional Milestone Buyout

Avalo Therapeutics (Nasdaq: AVTX) entered a Milestone Buyout Option and Amendment Agreement related to its March 2024 acquisition of AlmataBio.

Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) entered a Milestone Buyout Option and Amendment Agreement related to its March 2024 acquisition of AlmataBio. Avalo paid $2.25 million for an option, exercisable within 90 days, to pay an additional $5.125 million in cash, stock, or combination.

If exercised, that payment replaces a previously disclosed $15 million contingent milestone tied to first patient dosing in a Phase 3 trial.

Positive

• Liability reduced from $15M contingent to potential $5.125M
• Option provides certainty with a defined 90-day decision window
• Flexible payment choice of cash, stock, or combination

Negative

• Immediate cash outflow of $2.25M
• Potential dilution if $5.125M paid in Avalo common stock

Argus Apr 28 session

-10.82% close to close Open Argus

Details

News Market Reaction – AVTX

In the Apr 28 session, AVTX declined 10.82%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.8% in the session following this news. A negative reaction despite a restructu...

Analysis

The stock dropped -10.8% in the session following this news. A negative reaction despite a restructuring of milestone terms could reflect concern over near-term cash usage or future dilution rather than the economics alone. The company agreed to a $2.25 million payment plus an option for an additional $5.125 million in cash or stock, altering the prior $15 million contingent Phase 3 milestone. With an effective $750,000,000 shelf available, traders may have focused on the possibility of equity issuance even as Avalo manages legacy acquisition commitments.

Key Figures

Option payment: $2.25 million Additional buyout amount: $5.125 million Original milestone: $15 million +1 more

Option payment

$2.25 million

Milestone Buyout Option paid to former AlmataBio securityholders

Additional buyout amount

$5.125 million

Cash or stock payable if option is exercised within 90 days

Original milestone

$15 million

Previously disclosed contingent payment on first Phase 3 dosing

Option exercise window

90 days

Period from effective date to exercise Milestone Buyout Option

Historical Context

5 past events · Latest: Mar 23

5 events

1. Mar 23

   Earnings and update

   24h Move

   +0.6%

   2025 financials and cash runway into 2028 with higher R&D spending.

2. Feb 24

   Investor conferences

   24h Move

   +9.5%

   Participation in March 2026 healthcare investor conferences with webcasts.

3. Feb 18

   Inducement grants

   24h Move

   +6.5%

   Inducement stock options for new employees under Nasdaq Listing Rule 5635(c)(4).

4. Feb 04

   Investor conferences

   24h Move

   -10.0%

   February 2026 conference participation announcement with webcast availability.

5. Nov 17

   Inducement grants

   24h Move

   +6.7%

   Multiple stock option inducement grants to new hires under 2025 plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

milestone buyout option, contingent milestone payment, phase 3 trial

3 terms

milestone buyout option financial

"it has entered into a Milestone Buyout Option and Amendment Agreement"

A milestone buyout option is a contractual right allowing one party—often a licensee or partner—to pay a negotiated lump sum to eliminate future milestone-based payments or to acquire full rights tied to those milestones. For investors, it matters because exercising the option converts uncertain, contingent future income into a one-time payment or shifts future upside and obligations, changing a company’s revenue profile, risk exposure, and cash flow predictability much like settling a series of future installments with a single buyout.

contingent milestone payment financial

"in lieu of a previously disclosed $15 million contingent milestone payment"

A contingent milestone payment is money one party agrees to pay another only if specific, predefined goals or events are reached—such as regulatory approval, sales targets, or completion of a project. Think of it like a performance bonus that is only paid when the work is proven done. For investors, these payments matter because they shift risk and affect future cash flow and company value: they can reduce upfront cost but create potential future liabilities or dilution if targets are met.

phase 3 trial medical

"payment due upon the first patient being dosed in a Phase 3 trial"

A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the “Buyout Agreement”) related to the company’s prior acquisition of AlmataBio, Inc. in March of 2024.

Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.125 million in cash or shares of Avalo common stock, or a combination thereof in lieu of a previously disclosed $15 million contingent milestone payment due upon the first patient being dosed in a Phase 3 trial.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart (AVTX-009), is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalo Therapeutics (AVTX) agree to on April 28, 2026?

Avalo paid $2.25 million for an option tied to AlmataBio consideration. According to the company, the option is exercisable within 90 days to pay an additional $5.125 million in cash, stock, or both.

How does the buyout option change the previous $15 million milestone for AVTX?

The option replaces the prior $15 million contingent milestone with a potential $5.125 million payment. According to the company, this applies instead of the original payment tied to Phase 3 first patient dosing.

When must Avalo decide whether to exercise the AlmataBio buyout option (AVTX)?

Avalo has 90 days from the agreement's effective date to exercise the option. According to the company, exercise within that window triggers the additional $5.125 million payment in cash, shares, or both.

What are the payment methods Avalo can use if it exercises the option for AVTX?

If exercised, Avalo may pay the $5.125 million in cash, Avalo common stock, or a combination. According to the company, this flexibility is specified in the Buyout Agreement.

Does the buyout agreement require any immediate payment from Avalo (AVTX)?

Yes. Avalo made an immediate payment of $2.25 million to former AlmataBio securityholders. According to the company, that payment secures the 90-day option to settle the milestone differently.

What shareholder impacts should investors consider from Avalo's (AVTX) buyout option?

Key impacts include the $2.25 million cash outflow and possible share issuance if the $5.125 million is paid in stock. According to the company, payment method could affect cash balance or shareholder dilution.